We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Two New Rapid Tests Detect Ricin

By LabMedica International staff writers
Posted on 15 Apr 2009
New tests for ricin have been developed independently by two groups of scientists. More...
These tests could help safeguard people against potential acts of terrorism involving ricin and also have medical implications.

Ricin, a ribosomal inactivating protein found in castor beans, is one of the agents most likely to be used in acts of aerosol or food-related bioterrorism. It can be obtained easily, and quickly causes death when inhaled or eaten in small amounts. There is no known antidote. Quantitation of ricin also has medical applications, because ricin immunoconjugates have been used as anticancer agents. Current tests capable of identifying ricin by protein recognition methods exist but are generally slow, cumbersome, and inaccurate.

Vern Schramm and Matthew Sturm at the department of biochemistry, Albert Einstein College of Medicine of Yeshiva University (Bronx, NY, USA) developed a new test that detects the presence of active ricin in any sample by measuring the release of adenine from specific ricin substrates. Ricin-catalyzed adenine release from ribosomes stops protein synthesis and is the mechanism of action of this deadly toxin. By coupling adenine release to light formation by firefly luciferase, scientists can visualize the presence of ricin by the simple detection of light. The test can detect nanogram (one-billionth of a gram) amounts of ricin in minutes. A report of this test appeared online in the March 20, 2009 edition of Analytical Chemistry.

A highly selective three-part test was developed by John Barr and Suzanne Kalb from the U.S. Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA). The test involves capturing the ricin protein using special antibodies, evaluating the enzymatic activity of the ricin protein by mass spectrometry, and identifying the ricin protein by its amino acid sequence through mass spectrometry. In laboratory tests using small amounts of ricin spiked into food and body fluids, including milk, apple juice, serum, and saliva, the scientists found that the test was highly specific and accurate in comparison to current tests. This study appeared online in the February 19, 2009 publication of Analytical Chemistry.

Related Links:

Albert Einstein College of Medicine of Yeshiva University
United States Centers for Disease Control and Prevention




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Drug Testing Assays
Atellica DT 250 Analyzer
New
Slide Scanner System
NanoZoomer S540MD
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.